303 related articles for article (PubMed ID: 12422229)
1. Recognition and repair of DNA-cisplatin adducts.
Woźniak K; Błasiak J
Acta Biochim Pol; 2002; 49(3):583-96. PubMed ID: 12422229
[TBL] [Abstract][Full Text] [Related]
2. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM
Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor.
Zhai X; Beckmann H; Jantzen HM; Essigmann JM
Biochemistry; 1998 Nov; 37(46):16307-15. PubMed ID: 9819223
[TBL] [Abstract][Full Text] [Related]
4. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins.
Ohndorf UM; Rould MA; He Q; Pabo CO; Lippard SJ
Nature; 1999 Jun; 399(6737):708-12. PubMed ID: 10385126
[TBL] [Abstract][Full Text] [Related]
5. DNA sequence context and protein composition modulate HMG-domain protein recognition of cisplatin-modified DNA.
Dunham SU; Lippard SJ
Biochemistry; 1997 Sep; 36(38):11428-36. PubMed ID: 9298962
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin.
Takahara PM; Rosenzweig AC; Frederick CA; Lippard SJ
Nature; 1995 Oct; 377(6550):649-52. PubMed ID: 7566180
[TBL] [Abstract][Full Text] [Related]
7. Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts.
Ohndorf UM; Whitehead JP; Raju NL; Lippard SJ
Biochemistry; 1997 Dec; 36(48):14807-15. PubMed ID: 9398202
[TBL] [Abstract][Full Text] [Related]
8. Interaction between cisplatin-modified DNA and the HMG boxes of HMG 1: DNase I footprinting and circular dichroism.
Locker D; Decoville M; Maurizot JC; Bianchi ME; Leng M
J Mol Biol; 1995 Feb; 246(2):243-7. PubMed ID: 7869375
[TBL] [Abstract][Full Text] [Related]
9. Binding of Ixr1, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo.
McA'Nulty MM; Whitehead JP; Lippard SJ
Biochemistry; 1996 May; 35(19):6089-99. PubMed ID: 8634251
[TBL] [Abstract][Full Text] [Related]
10. Nature of full-length HMGB1 binding to cisplatin-modified DNA.
Jung Y; Lippard SJ
Biochemistry; 2003 Mar; 42(9):2664-71. PubMed ID: 12614161
[TBL] [Abstract][Full Text] [Related]
11. HMG1 protein inhibits the translesion synthesis of the major DNA cisplatin adduct by cell extracts.
Hoffmann JS; Locker D; Villani G; Leng M
J Mol Biol; 1997 Jul; 270(4):539-43. PubMed ID: 9245584
[TBL] [Abstract][Full Text] [Related]
12. Recognition of DNA interstrand cross-link of antitumor cisplatin by HMGB1 protein.
Kasparkova J; Delalande O; Stros M; Elizondo-Riojas MA; Vojtiskova M; Kozelka J; Brabec V
Biochemistry; 2003 Feb; 42(5):1234-44. PubMed ID: 12564926
[TBL] [Abstract][Full Text] [Related]
13. Nucleotide excision repair from site-specifically platinum-modified nucleosomes.
Wang D; Hara R; Singh G; Sancar A; Lippard SJ
Biochemistry; 2003 Jun; 42(22):6747-53. PubMed ID: 12779329
[TBL] [Abstract][Full Text] [Related]
14. Binding of nuclear proteins associated with mammalian DNA repair to the mitomycin C-DNA interstrand crosslink.
Warren AJ; Ihnat MA; Ogdon SE; Rowell EE; Hamilton JW
Environ Mol Mutagen; 1998; 31(1):70-81. PubMed ID: 9464318
[TBL] [Abstract][Full Text] [Related]
15. Effects of a piperidine ligand on DNA modification by antitumor cisplatin analogues.
Kasparkova J; Novakova O; Najajreh Y; Gibson D; Perez JM; Brabec V
Chem Res Toxicol; 2003 Nov; 16(11):1424-32. PubMed ID: 14615968
[TBL] [Abstract][Full Text] [Related]
16. Recognition of cisplatin adducts by cellular proteins.
Kartalou M; Essigmann JM
Mutat Res; 2001 Jul; 478(1-2):1-21. PubMed ID: 11406166
[TBL] [Abstract][Full Text] [Related]
17. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts.
Vaisman A; Lim SE; Patrick SM; Copeland WC; Hinkle DC; Turchi JJ; Chaney SG
Biochemistry; 1999 Aug; 38(34):11026-39. PubMed ID: 10460158
[TBL] [Abstract][Full Text] [Related]
18. Proteins that bind to and mediate the biological activity of platinum anticancer drug-DNA adducts.
Whitehead JP; Lippard SJ
Met Ions Biol Syst; 1996; 32():687-726. PubMed ID: 8640535
[No Abstract] [Full Text] [Related]
19. Modulation of MutS ATP-dependent functional activities by DNA containing a cisplatin compound lesion (base damage and mismatch).
Sedletska Y; Fourrier L; Malinge JM
J Mol Biol; 2007 May; 369(1):27-40. PubMed ID: 17400248
[TBL] [Abstract][Full Text] [Related]
20. Bypass of DNA lesions generated during anticancer treatment with cisplatin by DNA polymerase eta.
Alt A; Lammens K; Chiocchini C; Lammens A; Pieck JC; Kuch D; Hopfner KP; Carell T
Science; 2007 Nov; 318(5852):967-70. PubMed ID: 17991862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
